| Oct 16 |
IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug
|
| Oct 15 |
Immuneering rises on orphan drug designation for treatment of pancreatic cancer
|
| Oct 15 |
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
|
| Oct 14 |
Here's Why We're A Bit Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Situation
|
| Oct 2 |
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
|
| Sep 16 |
IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study
|
| Sep 13 |
Why Is Nanocap Immuneering Stock Trading Higher On Friday?
|
| Sep 12 |
Immuneering stock rockets 45% on pancreatic therapy data
|
| Sep 12 |
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
|
| Aug 29 |
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
|
